Jeil Pharmaceutical has signed a Joint Development and Technology Transfer Agreement with Autotelic Bio for the collaborative development of ATB-101, a fixed dose combination new drug for the treatment of hypertension and type 2 diabetes. The two companies plan to collaborate jointly to enter into global markets. 

Jeil Pharmaceutical has entered into a joint development agreement for ATB-101, which Autotelic Bio has demonstrated blood pressure lowering effects in animal model studies without using commonly used thiazide diuretics. 

Through this agreement, Jeil Pharmaceutical has secured exclusive distribution rights for the territories including Korea, China and Japan, as well as manufacturing rights of finished products for United States, which Autotelic Bio has the distribution rights. Autotelic Bio is planning to proceed with the U.S. clinical development of ATB-101 starting from the second half of 2019 using clinical sample products manufactured by Jeil Pharmaceutical, and at the same time, the two companies are planning to conduct joint development in Korea.